請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67485
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊曜宇(Eric Y. Chuang) | |
dc.contributor.author | Yi-Hsuan Chang | en |
dc.contributor.author | 張羿玄 | zh_TW |
dc.date.accessioned | 2021-06-17T01:34:17Z | - |
dc.date.available | 2020-09-07 | |
dc.date.copyright | 2017-09-07 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-01 | |
dc.identifier.citation | References
1. Silberberg, Y., et al., Large-scale elucidation of drug response pathways in humans. J Comput Biol, 2012. 19(2): p. 163-74. 2. Halvorsen, A.R., et al., Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy. Int J Cancer, 2014. 135(9): p. 2085-95. 3. Ritchie, M.D., et al., Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet, 2015. 16(2): p. 85-97. 4. Ansell, S.M., et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 2014. 372(4): p. 311-319. 5. Nanda, R., et al., Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol, 2016. 34(21): p. 2460-2467. 6. Rosenberg, S.A., et al., Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med, 1988. 319(25): p. 1676-1680. 7. Rizvi, N.A., et al., Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science, 2015. 348(6230): p. 124. 8. Loi, S., et al., Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol, 2014. 25(8): p. 1544-50. 9. Hackl, H., et al., Computational genomics tools for dissecting tumour-immune cell interactions. Nat Rev Genet, 2016. advance online publication. 10. Perou, C.M., et al., Molecular portraits of human breast tumours. Nature, 2000. 406(6797): p. 747-752. 11. Malhotra, G.K., et al., Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther, 2010. 10(10): p. 955-60. 12. Masood, S., Estrogen and progesterone receptors in cytology: A comprehensive review. Diagnostic Cytopathology, 1992. 8(5): p. 475-491. 13. Mohibi, S., et al., Mouse models of estrogen receptor-positive breast cancer. J Carcinog, 2011. 10: p. 35. 14. Trichopoulos, D., et al., Menopause and breast cancer risk2. J Natl Cancer Inst, 1972. 48(3): p. 605-613. 15. Cuzick, J., et al., Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol, 2015. 16(1): p. 67-75. 16. Haggar, F.A. and R.P. Boushey, Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg, 2009. 22(4): p. 191-197. 17. Manfredi, S., et al., Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg, 2006. 93(9): p. 1115-1122. 18. Siegel, R.L., et al., Cancer statistics, 2016. CA Cancer J Clin, 2016. 66(1): p. 7-30. 19. Subramanian, A., et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102: p. 15545-15550. 20. Chang, Y.-H., et al., Applying gene set analysis to characterize the activities of immune cells in estrogen receptor positive breast cancer. Transl Cancer Res, 2016. 5(2): p. 176-185. 21. Angelova, M., et al., Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol, 2015. 16: p. 64. 22. Sotiriou, C., et al., Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst, 2006. 98(4): p. 262-72. 23. Wang, Y., et al., Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 2005. 365(9460): p. 671-9. 24. Liberzon, A., et al., Molecular signatures database (MSigDB) 3.0. Bioinformatics, 2011. 27(12): p. 1739-40. 25. Hsu, Y.-C., et al., A gene-set approach to analyze copy number alterations in breast cancer. Transl Cancer Res, 2015. 4(3): p. 291-302. 26. Du, P., et al., Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics, 2010. 11: p. 587. 27. Geurts, P., D. Ernst, and L. Wehenkel, Extremely randomized trees. Machine learning, 2006. 63(1): p. 3-42. 28. Dennis, G., et al., DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol, 2003. 4(9): p. R60. 29. Ivshina, A.V., et al., Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res, 2006. 66(21): p. 10292-301. 30. Charoentong, P., et al., Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep, 2017. 18(1): p. 248-262. 31. Gajewski, T.F., H. Schreiber, and Y.-X. Fu, Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol, 2013. 14(10): p. 1014-1022. 32. Vesely, M.D., et al., Natural innate and adaptive immunity to cancer. Annu Rev Immunol, 2011. 29: p. 235-71. 33. Dabiri, S., et al., The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol, 2004. 17(6): p. 690-5. 34. Rajput, A.B., et al., Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat, 2008. 107(2): p. 249-257. 35. DeNardo, D.G. and L.M. Coussens, Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res, 2007. 9(4): p. 212. 36. Bertucci, F., et al., Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet, 2002. 11(8): p. 863-72. 37. Wilson, B.G. and C.W.M. Roberts, SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer, 2011. 11(7): p. 481-492. 38. Smid, M., et al., Subtypes of breast cancer show preferential site of relapse. Cancer Res, 2008. 68(9): p. 3108-14. 39. Liu, F., et al., CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat, 2011. 130(2): p. 645-655. 40. Bates, G.J., et al., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol, 2006. 24(34): p. 5373-80. 41. Whiteside, T.L., What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol, 2012. 22(4): p. 327-334. 42. Ferrone, S. and T.L. Whiteside, Tumor microenvironment and immune escape. Surg Oncol Clin N Am, 2007. 16(4): p. 755-74, viii. 43. Imada, A., et al., Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J, 2000. 15(6): p. 1087-1093. 44. Conti, P., et al., Role of mast cells in tumor growth. Ann Clin Lab Sci, 2007. 37(4): p. 315-22. 45. Shen, H., et al., The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res, 2008. 68(24): p. 10154-62. 46. Bochar, D.A., et al., BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell, 2000. 102(2): p. 257-265. 47. Ott, V.L., et al., Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol, 2003. 4(10): p. 974-981. 48. Mahnke, K., et al., Tolerogenic dendritic cells and regulatory T cells: A two-way relationship. J Dermatol Sci, 2007. 46(3): p. 159-167. 49. Mankoo, P.K., et al., Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. PLOS ONE, 2011. 6(11): p. e24709. 50. Holzinger, E.R., et al., ATHENA: the analysis tool for heritable and environmental network associations. Bioinformatics, 2014. 30(5): p. 698-705. 51. Strobl, C., et al., Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinformatics, 2007. 8: p. 25. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67485 | - |
dc.description.abstract | 免疫治療藉著活化病人體內的免疫反應來對抗腫瘤,近年來快速的發展且逐漸被應用在一些癌症之中。部分研究指出腫瘤免疫浸潤以及腫瘤抗原特異性會顯著的影響到免疫治療的效果以及病人的預後,因此為了提升免疫治療的效果,腫瘤免疫浸潤的含量便成為一個評估病人免疫治療效果以及預後的重要指標,如何找出影響免疫浸潤的生物標記也成為現今研究的主要趨勢。
在此論文中我們建立了兩套方法整合常見的體學資訊,包含了基因體、轉錄體、表觀遺傳體以及免疫基因體來觀察多重體學綜合下來對癌症患者中腫瘤免疫浸潤基因群以及預後的影響性。第一種方式是利用基因群分析找出和癌症預後顯著相關的免疫浸潤細胞種類,並且透過聚類分析探討差異表現的基因群可能調控的生物途徑。在第二種方法之中,我們結合腫瘤基因體學以及免疫基因體學,並利用隨機森林分類法篩選出對腫瘤免疫浸潤含量高低具有影響性的特徵,接著透過特徵重要性排序以及功能性註解找出潛在的分子機轉功能。我們將設計出來的兩種方法運用在GEO乳癌患者資料以及TCGA的大腸直腸癌患者資料上,分析腫瘤浸潤免疫細胞與預後之關係。在雌激素受體表達的乳癌患者之中發現有九種免疫浸潤細胞會顯著影響患者預後,並且於其中找出了先天與後天免疫浸潤細胞的互動關係,證實了腫瘤免疫浸潤細胞會共同調控患者之預後。另外在大腸癌患者中,透過特徵篩選以及隨機森林演算法成功鑑別出二十一種免疫細胞浸潤含量的高低,並於兩種免疫浸潤細胞中發現免疫球蛋白受體相關生物功能參與了免疫浸潤細胞含量的調控,顯示了我們結合多種體學特徵能夠更完整的找出影響免疫浸潤細胞含量的生物標記。 總結而言,本實驗系統性的探討了腫瘤免疫細胞浸潤的相關生物標記,並證明免疫細胞浸潤具有預測病人預後的潛力,期盼藉此為免疫治療效益以及病人預後的評估提供幫助,也進一步瞭解腫瘤免疫間的交互作用。 | zh_TW |
dc.description.abstract | Immunotherapy is a treatment that activates immune responses to fight tumors. This therapeutic option has advanced rapidly in recent years and been applied to certain cancers. Previous researches have indicated that both tumor-infiltrating lymphocytes (TILs) and antibody-neoantigen specificity have a great impact on the immunotherapeutic efficacy and the prognosis of cancer patients. Therefore, TILs are confirmed as an important indicator to enhance the therapeutic efficacy. Investigating specific biomarkers for TILs then becomes the current research trend.
We devised two methods to integrate multi-omics data, including genomics, transcriptomics, epigenomics and immunogenomics. Through integration of multi-omics data, we can explore the association between TILs and tumor prognosis. In the first method, we employed gene set approach to identify TILs relevant to tumor prognosis and investigated the biological pathway associated with differentially expressed TILs through clustering analysis. With the combination of the tumor genomics and the immunogenomics, we utilized the random forest classification as the second method to identify the characteristics which affected the quantity of TILs. Thus, we can explore potential molecular mechanisms by ranking feature importance and functional annotation. We applied the methods mentioned above to the breast cancer cohorts from GEO and the CRC cohorts from TCGA and analyzed the association between TILs and the prognosis. The results indicated that 9 TILs subtypes significantly associated with ER+ breast cancer patient prognosis. Furthermore, we revealed the interaction of innate and adaptive immune cells demonstrating the co-regulation of TILs on the breast cancer patient prognosis. On the other hand, we successfully separated CRC patients with high expression TILs from low expression TILs in 21 subtypes by random forest algorithm. We also found the immunoglobulin-related pathways involved in regulation of two TILs subtypes in CRC patients. The results suggest the incorporation of multi-omics data could comprehensively identify the important biomarkers for TILs. Overall, our study systematically investigated biomarkers associated with TILs and revealed the evidences that TILs were potential predictors for tumor prognosis. The findings are expected to facilitate the evaluation of immunotherapy response and enhance our understanding of tumor-immune interaction. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:34:17Z (GMT). No. of bitstreams: 1 ntu-106-R04945039-1.pdf: 5087431 bytes, checksum: 16fe3bf97f0f44ab644d053275494862 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員審定書 #
誌謝 I 中文摘要 II Abstract III List of Figures IX List of Tables X Chapter 1 Introduction 1 1.1 High-throughput omics data 1 1.2 Cancer immunotherapy and immunogemomics study 1 1.3 Breast cancer 3 1.4 Colorectal cancer 3 1.5 Gene set based analysis 4 1.6 Overall design of this study 4 1.6.1 Characterize breast cancer immune infiltration by gene set approach 5 1.6.2 Characterize colorectal cancer immune infiltration by random forest algorithm 5 Chapter 2 Materials and Methods 6 2.1 Gene set approach for characterizing TILs 6 2.1.1 Analysis framework 6 2.1.2 Gene set enrichment score 7 2.1.3 Survival analysis of enrichment score and association analysis 7 2.1.4 Gene set enrichment analysis of immune subtypes 8 2.2 Integrative analysis of multi-omics for characterizing TILs 9 2.2.1 Multi-dimensional data processing framework 9 2.2.2 Preselection of features associated with TILs 10 2.2.3 Random forest feature selection and classifier 11 2.2.4 Function analysis of TILs associated genome features 12 2.3 Materials 12 2.3.1 Immune gene sets 12 2.3.2 Patient data and genetic profiles 13 Chapter 3 Results 14 3.1 Results of TILs gene set association analysis 14 3.1.1 Predictive immune signatures for breast cancer prognosis 14 3.1.2 Validation for the identified predictive TIL subtypes 15 3.1.3 Multi-variate Cox analysis with other prognostic features 15 3.1.4 Construction the TIL interaction network 16 3.1.5 Functional relevance in the integrative subgroups 17 3.2 Results of multi-omics features analysis for TILs in CRC 18 3.2.1 Study Overview 18 3.2.2 Random forest identifies important features in CRC immune infiltration 19 3.2.3 Colorectal patient prognosis with immune infiltration 21 3.2.4 Functional annotation on TILs-associated important features and features correlation network 22 Chapter 4 Discussion 24 4.1 Gene set approach to study immune activities in ER+ breast cancer 24 4.2 Machine learning approach to study immune activities in CRC 28 Chapter 5 Conclusion 31 Figures 32 Tables 41 References 44 Appendix 48 | |
dc.language.iso | en | |
dc.title | 整合多重基因體資料以分析腫瘤浸潤免疫細胞與預後之關係 | zh_TW |
dc.title | Integrate Multi-omics Data to Explore Association between Tumor-Infiltrating Lymphocytes and Tumor Prognosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蕭自宏(Tzu-Hung Hsiao) | |
dc.contributor.oralexamcommittee | 蔡孟勳(Mon-Hsun Tsai),賴亮全(Liang-Chuan Lai),盧子彬(Tzu-Pin Lu) | |
dc.subject.keyword | 腫瘤免疫浸潤,基因群分析,隨機森林,多重體學,存活分析, | zh_TW |
dc.subject.keyword | Tumor-infiltrating lymphocytes,Gene set analysis,Random forest,Multi-omics,Survival analysis, | en |
dc.relation.page | 55 | |
dc.identifier.doi | 10.6342/NTU201702340 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-02 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 4.97 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。